Adjuvant trastuzumab: does time really matter?.
Citation: Oncologist. 18(5):490-2, 2013.PMID: 23624497Institution: Washington Cancer InstituteForm of publication: Journal ArticleMedline article type(s): Journal ArticleSubject headings: *Antibodies, Monoclonal, Humanized/ad [Administration & Dosage] | *Breast Neoplasms/dt [Drug Therapy] | *Chemotherapy, Adjuvant | Breast Neoplasms/pa [Pathology] | Clinical Trials as Topic | Drug Approval | Female | Humans | Receptor, erbB-2/ge [Genetics]Year: 2013Local holdings: Available online from MWHC library: 1996 - presentISSN:- 1083-7159
Item type | Current library | Collection | Call number | Status | Date due | Barcode |
---|---|---|---|---|---|---|
Journal Article | MedStar Authors Catalog | Article | 23624497 | Available | 23624497 |
Available online from MWHC library: 1996 - present
English